O-RADS超声与O-RADS MRI用于卵巢及附件病变风险评估的系统综述与Meta分析
该系统综述与Meta分析纳入26项研究共9520例患者,评估O-RADS超声与O-RADS MRI对卵巢或附件病变恶性诊断的效能:O-RADS超声汇总敏感度95%(95%CI 91-97%)、特异度82%(95%CI 76-87%),O-RADS MRI汇总敏感度95%(95%CI 92-97%)、特异度90%(95%CI 84-94%)。O-RADS超声与IOTA简单规则及ADNEX模型在头对头比较中敏感度和特异度均无显著差异。
要点
- O-RADS超声与O-RADS MRI对卵巢或附件恶性病变均具有高敏感度(均为95%)。
- O-RADS MRI特异度90%,高于O-RADS超声的82%。
- O-RADS超声与IOTA简单规则、ADNEX模型头对头比较无显著差异。
核心结论
- O-RADS超声和O-RADS MRI对卵巢或附件恶性肿瘤均具有高敏感度;O-RADS MRI还具有高特异度,而O-RADS超声无高特异度。
研究设计与样本
- 系统综述与Meta分析,检索Web of Science、PubMed、Cochrane Library、Embase和Google Scholar数据库2020年1月1日至2022年10月31日文献,纳入26项研究共9520例患者,其中O-RADS超声评估15项、O-RADS MRI评估12项、两者均评估1项;采用QUADAS-2评估研究质量,采用分层汇总ROC模型估计汇总敏感度和特异度,采用Q统计量评估异质性,并行Meta回归分析。
诊断标准与关键数值
- O-RADS超声汇总敏感度95%(95%CI 91-97%)、汇总特异度82%(95%CI 76-87%);O-RADS MRI汇总敏感度95%(95%CI 92-97%)、汇总特异度90%(95%CI 84-94%)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 质量评估显示偏倚风险或适用性疑虑最常与患者选择相关。
- Q统计量分析显示O-RADS超声研究间敏感度和特异度均存在显著异质性(均p < .001)。
- Q统计量分析显示O-RADS MRI研究间特异度存在显著异质性(p < .001),而敏感度无显著异质性(p = .07)。
- Meta回归分析中未发现任何因素与两种系统的敏感度或特异度显著相关(均p > .05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. O-RADS ultrasound (US) and O-RADS MRI have been developed to standardize risk stratification of ovarian and adnexal lesions. OBJECTIVE. The purpose of this study was to perform a meta-analysis evaluating the diagnostic performance of O-RADS US and O-RADS MRI for risk stratification of ovarian and adnexal lesions. EVIDENCE ACQUISITION. We searched the Web of Science, PubMed, Cochrane Library, Embase, and Google Scholar databases from January 1, 2020, until October 31, 2022, for studies reporting on the performance of O-RADS US or O-RADS MRI in the diagnosis of malignancy of ovarian or adnexal lesions. Study quality was assessed with QUADAS-2. A hierarchic summary ROC model was used to estimate pooled sensitivity and specificity. Heterogeneity was assessed with the Q statistic. Metaregression analysis was performed to explore potential sources of heterogeneity. O-RADS US was compared with the International Ovarian Tumor Analysis (IOTA) simple rules and Assessment of Different Neoplasias in the Adnexa (ADNEX) model in studies providing head-to-head comparisons. EVIDENCE SYNTHESIS. Twenty-six studies comprising 9520 patients were included. O-RADS US was evaluated in 15 and O-RADS MRI in 12 studies; both systems were evaluated in one of the studies. Quality assessment revealed that risk of bias or concern about applicability most commonly related to patient selection. Pooled sensitivity and specificity of O-RADS US were 95% (95% CI, 91-97%) and 82% (95% CI, 76-87%) and of O-RADS MRI were 95% (95% CI, 92-97%) and 90% (95% CI, 84-94%). Analysis with the Q statistic revealed significant heterogeneity among studies of O-RADS US in both sensitivity and specificity (both p < .001) and among studies of O-RADS MRI in specificity (p < .001) but not sensitivity (p = .07). In metaregression, no factor was significantly associated with sensitivity or specificity of either system (all p > .05). O-RADS US showed no significant difference in sensitivity or specificity versus IOTA simple rules in four studies (sensitivity, 96% vs 93%; specificity, 76% vs 82%) or versus the ADNEX model in three studies (sensitivity, 96% vs 96%; specificity, 79% vs 78%). CONCLUSION. O-RADS US and O-RADS MRI both have high sensitivity for ovarian or adnexal malignancy. O-RADS MRI, but not O-RADS US, also has high specificity. CLINICAL IMPACT. Awareness of the diagnostic performance results regarding O-RADS US and O-RADS MRI will be helpful as these systems are increasingly implemented into clinical practice.
引用
- Zhang Q, Dai X, Li W, et al. Systematic Review and Meta-Analysis of O-RADS Ultrasound and O-RADS MRI for Risk Assessment of Ovarian and Adnexal Lesions. AJR Am J Roentgenol. 2023. PMID: 36722758. doi:10.2214/AJR.22.28396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。